Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

The Chromatin Remodeler BPTF Activates a Stemness Gene-Expression Program Essential for the Maintenance of Adult Hematopoietic Stem Cells.

Xu B, Cai L, Butler JM, Chen D, Lu X, Allison DF, Lu R, Rafii S, Parker JS, Zheng D, Wang GG.

Stem Cell Reports. 2018 Mar 13;10(3):675-683. doi: 10.1016/j.stemcr.2018.01.020. Epub 2018 Feb 15.

2.

Structural basis for DNMT3A-mediated de novo DNA methylation.

Zhang ZM, Lu R, Wang P, Yu Y, Chen D, Gao L, Liu S, Ji D, Rothbart SB, Wang Y, Wang GG, Song J.

Nature. 2018 Feb 15;554(7692):387-391. doi: 10.1038/nature25477. Epub 2018 Feb 7.

3.

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.

Lu R, Wang GG.

Front Oncol. 2017 Oct 12;7:241. doi: 10.3389/fonc.2017.00241. eCollection 2017. Review.

4.

Gene enhancer deregulation and epigenetic vulnerability.

Lu R, Wang GG.

Oncoscience. 2016 Dec 21;3(11-12):299-301. doi: 10.18632/oncoscience.334. eCollection 2016. No abstract available.

5.

BPTF Is Essential for T Cell Homeostasis and Function.

Wu B, Wang Y, Wang C, Wang GG, Wu J, Wan YY.

J Immunol. 2016 Dec 1;197(11):4325-4333. Epub 2016 Oct 31.

6.

Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.

Lu R, Wang P, Parton T, Zhou Y, Chrysovergis K, Rockowitz S, Chen WY, Abdel-Wahab O, Wade PA, Zheng D, Wang GG.

Cancer Cell. 2016 Jul 11;30(1):92-107. doi: 10.1016/j.ccell.2016.05.008. Epub 2016 Jun 23.

7.

PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.

Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J.

Cancer Res. 2016 Feb 1;76(3):619-29. doi: 10.1158/0008-5472.CAN-15-1566. Epub 2016 Jan 8.

8.

An Allosteric Interaction Links USP7 to Deubiquitination and Chromatin Targeting of UHRF1.

Zhang ZM, Rothbart SB, Allison DF, Cai Q, Harrison JS, Li L, Wang Y, Strahl BD, Wang GG, Song J.

Cell Rep. 2015 Sep 1;12(9):1400-6. doi: 10.1016/j.celrep.2015.07.046. Epub 2015 Aug 20.

9.

Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Xu B, Konze KD, Jin J, Wang GG.

Exp Hematol. 2015 Aug;43(8):698-712. doi: 10.1016/j.exphem.2015.05.001. Epub 2015 May 28. Review.

10.

Histone modifications change with age, dietary restriction and rapamycin treatment in mouse brain.

Gong H, Qian H, Ertl R, Astle CM, Wang GG, Harrison DE, Xu X.

Oncotarget. 2015 Jun 30;6(18):15882-90.

11.

Polycomb genes, miRNA, and their deregulation in B-cell malignancies.

Wang GG, Konze KD, Tao J.

Blood. 2015 Feb 19;125(8):1217-25. doi: 10.1182/blood-2014-10-606822. Epub 2015 Jan 7. Review.

12.

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.

Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG.

Blood. 2015 Jan 8;125(2):346-57. doi: 10.1182/blood-2014-06-581082. Epub 2014 Nov 13.

13.

NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function.

Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD.

Cancer Discov. 2014 May;4(5):564-77. doi: 10.1158/2159-8290.CD-13-0419. Epub 2014 Feb 17.

14.

Tudor: a versatile family of histone methylation 'readers'.

Lu R, Wang GG.

Trends Biochem Sci. 2013 Nov;38(11):546-55. doi: 10.1016/j.tibs.2013.08.002. Epub 2013 Sep 10. Review.

15.

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.

Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, Vedadi M, Jin J.

ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.

16.

An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.

Cai L, Rothbart SB, Lu R, Xu B, Chen WY, Tripathy A, Rockowitz S, Zheng D, Patel DJ, Allis CD, Strahl BD, Song J, Wang GG.

Mol Cell. 2013 Feb 7;49(3):571-82. doi: 10.1016/j.molcel.2012.11.026. Epub 2012 Dec 27.

17.

Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1 subunits of the Rpd3S/Sin3S corepressor complex.

Kumar GS, Chang W, Xie T, Patel A, Zhang Y, Wang GG, David G, Radhakrishnan I.

J Mol Biol. 2012 Sep 28;422(4):519-31. doi: 10.1016/j.jmb.2012.06.013. Epub 2012 Jun 21.

18.

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.

Chi P, Allis CD, Wang GG.

Nat Rev Cancer. 2010 Jul;10(7):457-69. doi: 10.1038/nrc2876. Review.

19.

Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.

Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, Wang Z, Ruthenburg AJ, Elenitoba-Johnson KS, Roeder RG, Allis CD.

Mol Cell. 2010 Jun 25;38(6):853-63. doi: 10.1016/j.molcel.2010.05.011. Epub 2010 Jun 10.

20.

Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression.

Wang Z, Song J, Milne TA, Wang GG, Li H, Allis CD, Patel DJ.

Cell. 2010 Jun 25;141(7):1183-94. doi: 10.1016/j.cell.2010.05.016. Epub 2010 Jun 10.

Supplemental Content

Loading ...
Support Center